My NCBI | Sign In
RSS Settings
  • Search: Storkus W

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 155

    1.

    Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.

    Lipscomb MW, Chen L, Taylor JL, Goldbach C, Watkins SC, Kalinski P, Butterfield LH, Wesa AK, Storkus WJ.

    J Immunol. 2009 Dec 1;183(11):7250-8. Epub 2009 Nov 13.PMID: 19915058 [PubMed - in process]Related articles

    2.

    IL-4 Suppresses Very Late Antigen-4 Expression Which is Required for Therapeutic Th1 T-cell Trafficking Into Tumors.

    Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ.

    J Immunother. 2009 Sep 11. [Epub ahead of print]PMID: 19752754 [PubMed - as supplied by publisher]Related articles

    3.

    Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes.

    Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL.

    J Immunol. 2009 Sep 15;183(6):3720-30. Epub 2009 Aug 19.PMID: 19692638 [PubMed - indexed for MEDLINE]Related articles

    4.

    Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

    Kawabe M, Mandic M, Taylor JL, Vasquez CA, Wesa AK, Neckers LM, Storkus WJ.

    Cancer Res. 2009 Sep 1;69(17):6995-7003. Epub 2009 Aug 18.PMID: 19690146 [PubMed - indexed for MEDLINE]Related articles

    5.

    Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.

    Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ.

    Cancer Gene Ther. 2009 Dec;16(12):883-91. Epub 2009 May 15.PMID: 19444303 [PubMed - in process]Related articles

    6.

    Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine.

    Gigante M, Blasi A, Loverre A, Mancini V, Battaglia M, Selvaggi FP, Maiorano E, Napoli A, Castellano G, Storkus WJ, Gesualdo L, Ranieri E.

    Mol Immunol. 2009 Feb;46(5):893-901. Epub 2008 Nov 28.PMID: 19041139 [PubMed - indexed for MEDLINE]Related articles

    7.

    Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.

    Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T, Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ.

    J Immunol. 2008 Dec 1;181(11):7721-7.PMID: 19017961 [PubMed - indexed for MEDLINE]Related articles

    8.

    IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit.

    Sasaki K, Pardee AD, Okada H, Storkus WJ.

    Eur J Immunol. 2008 Oct;38(10):2865-73.PMID: 18958887 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth.

    Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, Alber S, Watkins SC, Pardee AD, Wesa AK, Storkus WJ.

    Cancer Res. 2008 Oct 1;68(19):8076-84.PMID: 18829566 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo.

    Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ.

    J Immunol. 2008 Jul 1;181(1):104-8.PMID: 18566374 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

    Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT.

    Clin Immunol. 2008 May;127(2):123-9. Review.PMID: 18405863 [PubMed - indexed for MEDLINE]Related articles

    12.

    Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.

    Gigante M, Mandic M, Wesa AK, Cavalcanti E, Dambrosio M, Mancini V, Battaglia M, Gesualdo L, Storkus WJ, Ranieri E.

    J Immunother. 2008 Apr;31(3):254-62.PMID: 18317362 [PubMed - indexed for MEDLINE]Related articles

    13.

    Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.

    Storkus WJ, Herrem C, Kawabe M, Cohen PA, Bukowski RM, Finke JH, Wesa AK.

    Crit Rev Immunol. 2007;27(5):485-93. Review.PMID: 18197809 [PubMed - indexed for MEDLINE]Related articles

    14.

    A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.

    Vujanovic L, Mandic M, Olson WC, Kirkwood JM, Storkus WJ.

    Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6796-806.PMID: 18006782 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.

    Wesa AK, Storkus WJ.

    Cell Death Differ. 2008 Jan;15(1):51-7. Epub 2007 Oct 19. Review.PMID: 17948028 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity.

    Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P.

    Cancer Res. 2007 Oct 15;67(20):10012-8.PMID: 17942935 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.

    Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N.

    Cancer. 2007 Oct 1;110(7):1469-77.PMID: 17685394 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.

    Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM.

    J Immunother. 2007 Sep;30(6):577-90. Review.PMID: 17667521 [PubMed - indexed for MEDLINE]Related articles

    19.

    Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors.

    Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H.

    Cancer Res. 2007 Jul 1;67(13):6451-8.PMID: 17616706 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Melanoma vaccines: in search of a clinical paradigm.

    Storkus WJ.

    Melanoma Res. 2007 Jun;17(3):137-8. No abstract available. PMID: 17505258 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    23 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity